The Chemical Checker provides processed, harmonized and ready-to-use bioactivity information on more than 1M small molecules
The tool, developed by the Structural Bioinformatics and Network Biology lab at IRB Barcelona, has been published in Nature Biotechnology.
The “Corporación Catalana de Medios Audiovisuales” has published a report on the RiPCoN project, in which IRB Barcelona’s Structural Bioinformatics and Network Biology is participating. Headed by Patrick Aloy, this lab is conducting a computational study of the interactions between the coronavirus and human cells with the aim to identify drugs already on the market or under development that can tackle the spread of the virus. The goal is to identify an antiviral treatment and, in the long-term, a possible vaccine.
In addition, various media have reported on the efforts made by IRB Barcelona to conduct mass screening for the disease.
Several media have reported on the collaboration between IRB Barcelona and Amazon. In this regard, IRB Barcelona’s Structural Bioinformatics and Network Biology Laboratory, headed by ICREA researcher Patrick Aloy, is collaborating with the American giant in the development of a tool based on Chemical Checker technology. This new tool aims to rapidly process the large volume of articles on COVID-19 and extract results that could be relevant in the search for a treatment.
The Structural Bioinformatics and Network Biology Lab is also participating in the European project RiPCoN, devoted to the identification of the human proteins that the virus uses for its...
· The tool is based on Chemical Checker technology, developed by the Structural Bioinformatics and Network Biology Laboratory at IRB Barcelona.
· The aim is to use artificial intelligence to generate a drug database that includes all the published scientific results related to the treatment of COVID-19.
· This open access database will provide researchers from around the world with an expanded portfolio of molecules with the potential to fight COVID-19.
The programme La Sexta Columna broadcasted by La Sexta has interviewed Patrick Aloy, head of the Structural Bioinformatics and Network Biology laboratory at IRB Barcelona, about the participation of his team in a European research project devoted to COVID-19. Aloy explains that the project will study the efficacy of more than 5000 drugs to fight this coronavirus. The scientist says, "If we do not get any results from these 5000 or 7000 compounds, we will have to widen the search and examine the million compounds that are available".
Link to: La Sexta Columna (minute 41: 10-42: 50)
The European Commission has awarded funding to 17 research projects in a special call announced to tackle the coronavirus. IRB Barcelona’s Structural Bioinformatics and Network Biology Lab, headed by Patrick Aloy, is participating in one of these projects, together with other research centres. The project, called RiPCoN, will perform a computational study of the interactions between coronavirus and human cells, with the aim to identify drugs (already on the market or in trials) that can halt the spread of the virus.
Various media have reported on Spain’s participation in 6 of the 17 projects chosen by the European Commission to advance and speed up research into the...
Infosalus, Medicina TV, Bolsamania, Bioengineer and Medi Magazine, among other national and international media, have published an article about the recent study led by the Structural Bioinformatics and Network Biology Lab. This research demonstrates that cancer cells proliferate less and in a less robust manner when their internal pH is lowered, that is to say it becomes more acidic.
Link to Infosalus
A new computational model has allowed researchers to identify new therapeutic targets that can attack cancer cells by lowering their intracellular pH.
The study, which is the result of collaboration between IRB Barcelona, the Moffitt Cancer Center, and the University of Maryland, has been published in Nature Communications.
BIST has selected 12 winners, among them Guiomar Solanas, Jelena Urosevic and Lidia Mateo.
This programme recognises excellence in research and supports women scientists in their transition to leadership positions.
Patrick Aloy, Group Leader of the Structural Bioinformatics and Network Biology Lab at IRB Barcelona participated in the "Càpsules de ciència” video series produced by TV3. In the video he talks about how they apply network biology to find a cure for diseases such as cancer and Alzheimer's.
Link to TV3